Panthera Biopartners signs two new clinical trial contracts over £10 million each
Panthera, the UK’s largest SMO (Site Management Organisation), has recently signed two clinical trial contracts worth over £10 million each. These trials for international pharma companies involve recruiting patients and running the clinical trials at its sites across the UK.
This continues a very successful run for Panthera, which had a record-breaking year in 2024.
Panthera, founded in 2019, has rapidly developed a model that provides its clients - pharma and CROs - with rapid enrollment and large numbers of patients. In the last two years, Panthera has been the top recruiter globally in four studies, the top recruiter in the UK on six other studies and has achieved first patient in globally or in the UK on nine studies.
Panthera works with 10 out of the top 12 pharma companies and seven of the top CROs and in 2024 became the first UK public or commercial clinical trial organisation to become part of Parexel’s Site Alliance Vaccine Network.
Despite a decline in NHS-registered clinical trial enrolments, independent SMOs like Panthera are experiencing rapid growth. With more than 50 dedicated trial sites across the UK, this sector continues to expand, providing crucial services to pharmaceutical companies and Contract Research Organisations (CROs).
Unlike NHS figures, the contributions of SMOs are not included in ABPI or NHS statistics, underscoring the untapped potential of these organisations in driving clinical trial success.
The UK remains a top destination for clinical trials due to its dense and diverse population, high-calibre healthcare professionals, and recent regulatory advancements by the Medicines and Healthcare Products Regulatory Agency (MHRA). Changes to streamline regulatory reviews have enhanced the UK’s competitiveness against European countries while offering cost advantages over the US.
Panthera’s expanding UK network of dedicated clinical trial sites includes clinics in Glasgow, York, Sheffield, Preston, Rochdale and Enfield and carries out trials in vaccines, cardiovascular, general medicine, diabetes, neurology, respiratory, dermatology and rheumatology and also specialist areas such as oncology, NASH and early dementia trials.
